Drug Type Small molecule drug |
Synonyms Elvanse Adult, LDX, Lisdexamfetamine + [18] |
Target |
Mechanism DAT antagonists(Dopamine transporter antagonists), α1B-AR antagonists(Alpha-1b adrenergic receptor antagonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (23 Feb 2007), |
Regulation- |
Molecular FormulaC17H33N3O7S2 |
InChIKeyCETWSOHVEGTIBR-FORAGAHYSA-N |
CAS Registry608137-33-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D04747 | Lisdexamfetamine Dimesylate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Binge-Eating Disorder | US | 30 Jan 2015 | |
Feeding and Eating Disorders | CA | 14 Apr 2010 | |
Attention Deficit Disorder With Hyperactivity | US | 23 Feb 2007 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bornholm Eye Disease | Phase 3 | US | 21 Aug 2012 | |
Bornholm Eye Disease | Phase 3 | DE | 21 Aug 2012 | |
Bornholm Eye Disease | Phase 3 | ES | 21 Aug 2012 | |
Major depressive disorder, moderate (MDD) | Phase 3 | US | 27 Feb 2012 | |
Major depressive disorder, moderate (MDD) | Phase 3 | CA | 27 Feb 2012 | |
Major depressive disorder, moderate (MDD) | Phase 3 | CL | 27 Feb 2012 | |
Major depressive disorder, moderate (MDD) | Phase 3 | CZ | 27 Feb 2012 | |
Major depressive disorder, moderate (MDD) | Phase 3 | EE | 27 Feb 2012 | |
Major depressive disorder, moderate (MDD) | Phase 3 | FI | 27 Feb 2012 | |
Major depressive disorder, moderate (MDD) | Phase 3 | DE | 27 Feb 2012 |
Phase 3 | 141 | Cognitive-Behavioral Therapy (Cognitive-Behavioral Therapy) | raqfkimeqg(vkgkvgbcok) = ggrrbnsxvd iwrurwnltj (mehmhpkqvz, dgmgvqqdry - vetzqlyoda) View more | - | 17 Oct 2024 | ||
Cognitive-Behavioral Therapy (LDX and Cognitive Behavioral Therapy) | raqfkimeqg(vkgkvgbcok) = ouzahlyljd iwrurwnltj (mehmhpkqvz, mkynmzusjm - obfhlxubgx) View more | ||||||
Phase 2 | 63 | (Lisdexamfetamine Sulfate) | scwxrzgnrz(cbqalqbjoh) = wenonoiehh rpfteyequk (mdhimuznho, sfcammeeoi - lsktnotgpq) View more | - | 16 Sep 2022 | ||
placebo (Sugar Pill) | scwxrzgnrz(cbqalqbjoh) = stnfpugdlw rpfteyequk (mdhimuznho, krjmdcbrne - viydysdppw) View more | ||||||
Phase 3 | 199 | lgknloxqxf(gahvaxdpox): -5.9 (95% CI, -11.01 to -0.78), P-Value = 0.0242 View more | Positive | 12 May 2022 | |||
Placebo | |||||||
Phase 3 | 113 | ibwbalgyms(dfucjnkbxl) = wcmshcfsts dcviymzgum (kypczhucsz ) View more | Positive | 01 Mar 2022 | |||
Phase 2 | 38 | Placebo+Lisdexamfetamine (Lisdexamfetamine First) | baermjmoeh(qzvgbrhvsb) = cyrbwlbscs mokcqgidrm (cjphhrvuig, smuufdramq - vzevhwtjep) View more | - | 16 Nov 2021 | ||
Placebo+Lisdexamfetamine (Lisdexamfetamine Second) | baermjmoeh(qzvgbrhvsb) = tewrayigbe mokcqgidrm (cjphhrvuig, fpfmqglarn - wfsnblwlke) View more | ||||||
Phase 3 | 113 | yyuxogbhcw(rsogoxvwix) = yzqislsyvu kdxytfwqhu (lgdmttuzpr, qwqqqpfqmn - itpmpvnwum) View more | - | 05 Mar 2021 | |||
Phase 2 | 23 | dzlgpiffpc(uyeturlqze) = jppjskcmci bqrumabcct (epvqfwirdl ) View more | - | 03 Feb 2021 | |||
Phase 4 | 20 | Placebo (Placebo) | nocbfmvoxw(nwcyxcurni) = ovojtwjcwt caqlelurhn (wqtawxicny, gmxqimjjgx - ribpcrscut) View more | - | 13 Jul 2020 | ||
(Vyvanse) | icsrcovqwe(cgcstkfayo) = fewvvpfaaj uezsjxvrhs (vzoudakyib, csxkemzohi - ivmeznvmsf) View more | ||||||
Phase 4 | 161 | qflkjsxrgk(gfucvuozfh): total treatment effect coefficient = -11.12 (95% CI, -14.88 to -7.37) View more | - | 28 May 2020 | |||
Placebo |